Skip to main content

GENERAL COMMENTARY article

Front. Oncol., 30 November 2021
Sec. Radiation Oncology
This article is part of the Research Topic Principles and Clinical Applications of Interstitial Brachytherapy View all 9 articles

Commentary: “Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125 I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery”: Letter to the Editor

Enli ChenEnli Chen1Fenxian ZhangFenxian Zhang2Chenfei Jia*Chenfei Jia3*
  • 1Department of Oncology, Graduate School of Hebei Medical University, Hebei Medical University, Shijiazhuang, China
  • 2Department of Life Science, College of Life Science, Shanxi Agricultural University, Jinzhong, China
  • 3Department of Oncology, Cangzhou Central Hospital, Cangzhou, China

A Commentary on
Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery

By Wang H, Wang L, Jiang Y, Ji Z, Guo F, Jiang P, Li X, Chen Y, Sun H, Fan J, Du G and Wang J (2021). Front. Oncol. 10:540096. doi: 10.3389/fonc.2020.540096

Because 125 I seeds can deliver a high dose of radiation to the tumor target while sparing surrounding normal tissues, it is increasingly used for the treatment of various cancer types and has already achieved promising efficacy. In a recent retrospective study, Wang et al. (1) investigated the long-term efficacy and normal tissue toxicities experienced by 101 patients with locally recurrent rectal cancer (LRRC) after external beam radiotherapy or surgery treated by interstitial implantation of 125 I seeds. The study is of great significance in the treatment of LRRC, which offers a highly effective treatment. However, there are still some issues that we expect to discuss with the authors.

First, when they applied the Chi-square test and Fisher’s exact test to analyze factors correlated with adverse effects, they did not include the dose of the organ at risk (OAR) such as D2cc or D0.1cc of skin or mucosa. It is well known that the dose of OAR is closely related to the occurrence of radiation damage (24). Therefore, we recommend that the authors further analyze the detailed relationship between the dose of OAR and radiation damage. We also hope that the authors can explore the cutoff value of the dose of OAR (when the dose of OAR is greater than this calculated cutoff value, radiation damage is more likely to occur). Such results may be more favorable to the formulation of a preoperative implantation plan to control post-implantation radiation damage. In addition, it is also necessary to include D100, V150, and V200, because D100 can reflect the dose in the peripheral area of the tumor, and V150 and V200 can reflect the volume of the high dose within the tumor target (5, 6). In our recent study (6), we found that the faster the tumor shrank, the more likely the 125 I seeds were to gather centrally, which might lead to the local ultra-high dose region, thereby causing radiation damage to surrounding normal tissues. If patients achieve complete remission over short periods, we believe that it is more likely to lead to radiation damage (6, 7). Thus, the short-term efficacy should also be included in the analysis of adverse effects.

Additionally, when they analyzed factors associated with local control (LC), they did not include all observed postoperative parameters such as D100, V150, homogeneity index (HI), conformal index (CI), and external index (EI), which we suppose are of paramount importance. We suggest that the authors include these missing parameters recorded. Another issue is how is the cutoff value calculated? For example, why is D90 grouped by 129 Gy? Why is GTV grouped by 50 cm3? Unfortunately, we did not find the grouping basis in the Method section of the article. We hold that the most scientific approach is to use X-tile software to determine the cutoff value for all the continuous data (8). Furthermore, as the authors stated, treatment modalities used for LRRC patients after 125 I seed implantation were not consistent as well; some patients received postoperative chemotherapy, which, however, was poorly tolerated by other patients. It is well known that the combination of radiotherapy and chemotherapy can contribute to significant improvements in local tumor control and cure rates. Thus, it is recommended to include postoperative chemotherapy for covariate adjustment when the Cox proportional hazards regression model is used for multivariate analysis.

In conclusion, the authors left out some important variables in their analysis of adverse effects, and they failed to include postoperative chemotherapy for covariate adjustment in multivariate analysis of LC. In addition, they did not state the grouping basis of continuous data in the Method section of the article. We believe that the most scientific approach is to use X-tile software to determine the cutoff value for all the continuous data.

Author Contributions

EC, FZ, and CJ wrote the letter. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

The authors would like to thank the participating members. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Wang H, Wang L, Jiang Y, Ji Z, Guo F, Jiang P, et al. Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125i Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery. Front Oncol (2021) 21(10):540096. doi: 10.3389/fonc.2020.540096

CrossRef Full Text | Google Scholar

2. Jiang Y, Ji Z, Guo F, Peng R, Sun H, Fan J, et al. Side Effects of CT-Guided Implantation of 125I Seeds for Recurrent Malignant Tumors of the Head and Neck Assisted by 3D Printing Non-Co-Planar Template. Radiat Oncol (2018) 13(1):18. doi: 10.1186/s13014-018-0959-4

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Mao MH, Zhang JG, Zheng L, Gao H, Zhang J, Liu SM, et al. The Incidence of Radioepidermitis and the Dose-Response Relationship in Parotid Gland Cancer Patients Treated With 125I Seed Brachytherapy: Incidence of Radioepidermitis and the Dose-Response Relationship. Strahlenther Onkol (2015) 191(1):26–33. doi: 10.1007/s00066-014-0738-6

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Kuo HC, Mehta KJ, Yaparpalvi R, Shankar V, Bodner W, Garg M, et al. Model Assessment of Individual Tumor Control Rate and Adverse Effects in Comparing Locally Advanced Cervical Cancer Treatment Using Intracavitary With and Without Interstitial Brachytherapy. J Contemp Brachytherapy (2016) 8(6):525–32. doi: 10.5114/jcb.2016.64743

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Okazaki E, Kuratsukuri K, Nishikawa T, Tanaka T, Sakagami M, Shibuya K. Comparison of Post-Implant Dosimetrics Between Intraoperatively Built Custom-Linked Seeds and Loose Seeds by Sector Analysis at 24 Hours and 1 Month for Localized Prostate Cancer. J Contemp Brachytherarpy (2020) 12(4):317–26. doi: 10.5114/jcb.2020.98110

CrossRef Full Text | Google Scholar

6. Chen E, Wang J, Zhao J, Liu Z, Xu K, Liang Y, et al. Dynamic Dose Study of 125I Seed Implantation in Treating Recurrent and Metastatic Squamous Cell Carcinoma at Two Months After Surgery. J Intervent Radiol (2020) 29(3):262–6. doi: 10.3969/j.issn.1008-794X.2020.03.009

CrossRef Full Text | Google Scholar

7. Niu S, Di X, Du S, Shao Y, Zhang H, Wang J. The Effect of Tumor Volume Reduction on Duodenal Dose After 125I Seed Implantation. Chin J Radiol Med Prot (2017) 37(3):209–11. doi: 10.3760/cma.j.issn.0254-5098.2017.03.009

CrossRef Full Text | Google Scholar

8. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res (2004) 10(21):7252–9. doi: 10.1158/1078-0432.CCR-04-0713

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: locally recurrent rectal cancer (LRRC), 125 I seed implantation, dosimetry, prognosis, adverse effects

Citation: Chen E, Zhang F and Jia C (2021) Commentary: “Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125 I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery”: Letter to the Editor. Front. Oncol. 11:750922. doi: 10.3389/fonc.2021.750922

Received: 31 July 2021; Accepted: 10 November 2021;
Published: 30 November 2021.

Edited by:

Nikolaos Zamboglou, German Oncology Center, Cyprus

Reviewed by:

Alexander Heriot, Peter MacCallum Cancer Centre, Australia

Copyright © 2021 Chen, Zhang and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chenfei Jia, ZG9jamNmIEAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.